Key Points
- Kura Oncology insider Mollie Leoni sold 12,448 shares at an average price of $10.50, worth $130,704, reducing her position by 6.83% to 169,897 shares. She also sold 28,802 shares the following day for approximately $309,622.
- KURA opened at $10.81, with a market capitalization of about $961.7 million and a 52-week range of $7.36 to $13.90. The company recently reported a quarterly loss of $0.77 per share, beating the $0.88 consensus estimate, alongside $20.87 million in revenue.
- Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $25.40, substantially above the reported share price.
Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) COO Kathleen Ford sold 3,668 shares of the business's stock in a transaction that occurred on Tuesday, September 29th. The shares were sold at an average price of $10.75, for a total value of $39,431.00. Following the transaction, the chief operating officer directly owned 142,986 shares in the company, valued at $1,537,099.50. This trade represents a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Kathleen Ford also recently made the following trade(s):
- On Monday, September 28th, Kathleen Ford sold 6,906 shares of Kura Oncology stock. The stock was sold at an average price of $10.50, for a total value of $72,513.00.
Kura Oncology Stock Performance
Shares of KURA stock opened at $10.81 on Wednesday. The firm has a market capitalization of $961.67 million, a price-to-earnings ratio of -3.21 and a beta of 0.44. The stock has a fifty day moving average of $11.22 and a 200 day moving average of $10.16. Kura Oncology, Inc. has a 52 week low of $7.36 and a 52 week high of $13.90. The company has a quick ratio of 4.71, a current ratio of 4.73 and a debt-to-equity ratio of 0.12.
Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.88) by $0.11. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%. The business had revenue of $20.87 million for the quarter, compared to the consensus estimate of $20.16 million. As a group, research analysts expect that Kura Oncology, Inc. will post -3.25 earnings per share for the current year.
Kura Oncology News Roundup
Here are the key news stories impacting Kura Oncology this week:
- Positive Sentiment: KO-7246 regenerated functional pancreatic beta-cell mass and improved glycemic control in Type 1 and Type 2 diabetes models. Benefits persisted for at least one month after treatment stopped in a Type 1 diabetes model, suggesting potential disease-modifying activity. KO-7246 EASD announcement
- Positive Sentiment: The candidate increased beta-cell mass, endogenous insulin and C-peptide levels, and showed enhanced activity when combined with semaglutide. Results in human pancreatic islets also indicated selective beta-cell proliferation and improved glucose-responsive insulin secretion, strengthening the potential commercial value of Kura’s menin-inhibitor platform. KO-7246 preclinical data
- Neutral Sentiment: KO-7246 remains preclinical. Caspian plans IND-enabling work and a future Phase 1 study, with management scheduled to discuss the program on October 13. Any valuation benefit for KURA therefore depends on future clinical progress and the terms of Kura’s relationship with Caspian. Caspian and Kura KO-7246 report
- Negative Sentiment: Several Kura executives and insiders sold shares on September 28–29, including Mollie Leoni, Brian Powl, Kathleen Ford, Thomas Doyle and Teresa Bair. The transactions totaled approximately 97,000 shares and more than $1 million, signaling near-term insider selling pressure even though the sellers retained substantial holdings. Kura insider ownership filing
- Negative Sentiment: The diabetes opportunity carries substantial execution risk, including potential clinical or regulatory setbacks, unexpected safety findings and the need for additional financing before human trials can begin.
Hedge Funds Weigh In On Kura Oncology
Several large investors have recently made changes to their positions in the business. BlackRock Inc. bought a new stake in shares of Kura Oncology in the 2nd quarter worth approximately $115,286,000. Bank of America Corp DE bought a new position in Kura Oncology during the 2nd quarter valued at approximately $12,735,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in Kura Oncology during the 2nd quarter valued at approximately $10,927,000. Man Group plc purchased a new position in Kura Oncology during the second quarter valued at $4,749,000. Finally, Pale Fire Capital SE raised its stake in Kura Oncology by 89.6% during the first quarter. Pale Fire Capital SE now owns 857,474 shares of the company's stock valued at $6,971,000 after buying an additional 405,229 shares during the last quarter.
Analyst Upgrades and Downgrades
Several equities analysts recently issued reports on KURA shares. Sanford C. Bernstein set a $24.00 price target on shares of Kura Oncology in a research report on Monday, June 15th. Citigroup reaffirmed a "market outperform" rating on shares of Kura Oncology in a research report on Monday, August 24th. Raymond James Financial set a $24.00 target price on Kura Oncology in a report on Monday, August 24th. Citizens Jmp reissued a "market outperform" rating and issued a $24.00 target price on shares of Kura Oncology in a research report on Monday, August 24th. Finally, Wedbush raised their target price on Kura Oncology from $36.00 to $38.00 and gave the company an "outperform" rating in a research note on Thursday, August 13th. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Kura Oncology currently has a consensus rating of "Moderate Buy" and an average target price of $25.40.
Check Out Our Latest Report on KURA
About Kura Oncology
(
Get Free Report)
Kura Oncology, Inc is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company's research programs target specific genetic and molecular abnormalities that contribute to tumor growth, with an emphasis on hematologic malignancies and selected solid tumors.
Kura's leading program has been ziftomenib, an oral, selective menin inhibitor being developed for genetically defined forms of acute myeloid leukemia, including cancers with NPM1 mutations or certain KMT2A rearrangements.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
